ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-positive chronic myeloid leukemia.